BTECH
NEWS highlights selected events in the life sciences sector that the
Btech Investor team believes are particularly relevant to biotechnology
investors.
No Evidence that Preos Increases Cancer Risk
Glivec (Gleevec) Use Likely to Increase in U.K.
Lining Up New Targets
Crestor Approval Concerns
Interim Raptiva (Xanelim) Data
BTECH WEEKLY REPORT: THE MOUSE GENOME REVEALED
Memantine NDA
Vernalis and Roche Cancel Development of Obesity Drug
Guidant Acquires Cook
Expanding Marketed Drugs into Alzheimer Treatment
Hurdles to Vevesca Approval
Vardenafil Approvable
Expansion of Statins and NSAIDs to Alzheimer Treatment
Aranesp Label Expanded
Statins for Alzheimer Disease
Memantine for Alzheimer Disease
Eprex Versus Aranesp
Genomics Derived Drug Enters Clinical Trials
Histone deacetylase inhibitors: Redefining pharmaceutical approaches to the treatment of cancer
BTECH WEEKLY REPORT: THALIDOMIDE, STATINS, AND ANGIOMAX
New Nitric Oxide Therapeutics
Alzheimer Disease Therapeutics After Betabloc
BTECH WEEKLY REPORT: EXPANDING INDICATIONS FOR REMICADE AND ENBREL
InFUSE Bone Graft Approved
New Trials for Insomnia, Diabetes, and Crohn Disease
The FDA Will Re-Examine Bexxar
A Statin A Day Keeps the Doctor Away
Molecular Classification of Disease
Setback for Vevesca Approval
Btech Weekly Report: Novel Aspects Of Diabetes Care
Xolair Approved in Australia
Highlights of the American Diabetes Association Meeting
Btech weekly report: Therapies for rheumatoid arthritis and psoriasis
Biogen Receives Complete Response Letter For Amevive
TKT's Progress At Replacing an Intracellular Enzyme
IDEC (NASDAQ: DPH) has halted clinical trials of its therapeutic monoclonal antibody IDEC-131
Btech Weekly Report: Scientific Advances In RNA Interference and Cloning
Btech Report: Biotechnology Industry Valuation
Tracleer Efficacious in Children for treatment of pulmonary arterial hypertension (PAH)
Platform Technology vs. Drug Discovery
INTERLEUKIN LAUNCHES A PHARMACOGENOMICS STUDY OF RHEUMATOID ARTHRITIS
Merz and Lundbeck received European Union marketing approval for Ebixa
(Memantine) for the treatment of Alzheimers
The American Society of Clinical Oncology (ASCO) meeting
AN AMERICAN COATED STENT IN PARIS.
RETURN
TO INDEX
BTECH NEWS, published by Btech Investor, Inc., highlights selected events in
the life sciences sector that the Btech Investor team believes are particularly relevant to biotechnology investors. The Btech Investor team
combines scientific, clinical, and business experience to perform comprehensive analysis of the biotechnology industry and to identify future
industry leaders.
BTECH INVESTOR REPORTS
The Btech Investor Reports provide in-depth analysis of the biotechnology
industry. Recent companies profiled include Vertex, EntreMed, Élan, IDEC
Pharmaceuticals, Myriad Genetics, and Abgenix. Recent sector reports include
nucleic acid therapeutics, Alzheimer disease, inhaled insulin, recombinant
proteins, gene therapy, monoclonal antibodies, neurodegenerative diseases,
stem cells, trends in oncology, genomics based drug discovery, and biotech
trends.
DISCLAIMER
Btech Investor aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no
representations or warranties, either express or implied of completeness,
accuracy, or of any other nature are made with respect to this information.
This information is neither an offer to sell nor a solicitation to buy the
securities of any company. This email contains forward-looking statements,
which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the
companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition
that the reader will make his or her own determination as to its suitability
for any purpose prior to any use of the information contained within this
email. The employees and officers of Btech Investor may hold positions in
some or all of the stocks discussed in this report.
© Copyright 2002, Btech Investor, Inc.
